Method of treating multiple sclerosis
OwnerBernard Bihari, Finvola Druryinventors
Life of this patent
Estimating the term…
Abstract
Multiple sclerosis in a human patient is treated by the administration via a pharmacologically effective route of an essentially pure opiate receptor antagonist, preferably an essentially pure opiate receptor antagonist exhibiting a substantially higher blocking effectiveness against Mu opiate receptor sites than against Delta receptor sites, exempliefied by Naltrexone and Naloxone, at a low dose concentration which produces therapeutic results corresponding to those produced by Naltrexone when administered in the range of about 1 mg to about 10 mg and at a lelel at which Delta blocking activity is small while Mu blocking activity is significant and most preferably substantially exclusive.
Claims5
A method of treating humans suffering from multiple sclerosis, which comprises the step of administering by a pharmacologically effective mode to such patient a therapeutically effective dose of a therapeutic agent consisting essentially of an essentially pure opiate receptor antagaonist, the amount of said dose being selected to produce therapeutic results substantially corresponding to those produced by Naltrexone when administered in the range of about 1 mg to about 10 mg.
A method of treating humans suffering from multiple sclerosis, which comprises the step of administering by a pharmacologically effective mode to such patient a therapeutic agent consisting essentially of an essentially pure opiate receptor antagonist having a selectively higher blocking action against Mu opiate receptors than against Delta receptors in an amount which is effective to exert a substantial opiate blocking action against Mu receptors but insufficient to exert such action against Delta receptors.
A method of treating humans suffering from multiple sclerosis, which comprises the step of administering by a pharmacologically mode to such patient a therapeutically effective dose of an essentially pure opiate receptor antagonist, the amount of said dose being selected to produce therapeutic results corresponding substantially to those produced by Naltrexone when administered in the range of about 1 mg to about 10 mg and at a level within said range exerting an opiate blocking action substantially exclusively for Mu opiate receptors.
Dependencies are inferred from the claim text.